Last reviewed · How we verify
AC VAX
AC VAX is a vaccine that stimulates the body's immune system to produce antibodies against a specific antigen.
AC VAX is a vaccine that stimulates the body's immune system to produce antibodies against a specific antigen. Used for COVID-19 prevention.
At a glance
| Generic name | AC VAX |
|---|---|
| Sponsor | Astellas Pharma Inc |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
AC VAX works by introducing a small, harmless piece of the antigen to the body, which triggers an immune response and allows the body to recognize and attack the antigen if it enters the body in the future.
Approved indications
- COVID-19 prevention
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AC VAX CI brief — competitive landscape report
- AC VAX updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI